IP Library › Granted Patent US 11,596,656
Granted Patent B2
US 11,596,656 · App. 16/327,402 · Granted Mar 7, 2023

Stem cell-produced microvesicles for treating tendon pathologies

Inventor: Hui B. Sun (Chappaqua, NY)
Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
A61K35/28C12N5/066C12N5/0668C12N2533/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,596,656
App. No.
16/327,402
Granted
Mar 7, 2023
Kind
B2
Abstract

Microvesicles produced by stem cells grown on a silk scaffold for enhancing stem cell self-renewal/proliferation and promoting tenogenesis in damaged tendons, and their use in tendon wound repair and tendinopathy treatment. Also provided are compositions containing the microvesicles and devices for obtaining them.

Claims (15)

1. A method of treating a damaged tendon in a mammalian subject comprising administering to the subject an amount of microvesicles derived from mammalian mesenchymal stem cells effective to treat a damaged tendon, wherein the mesenchymal stem cells have been cultured on a silk scaffold prior to the microvesicles being derived from the mesenchymal stem cells.

2. The method of claim 1 , wherein the microvesicles have been secreted from mesenchymal stem cells.

3. The method of claim 1 , wherein the mesenchymal stem cells at P1 to P3 have been cultured on the silk scaffold.

4. The method of claim 1 , wherein the mesenchymal stem cells (MSC) are adipose-derived MSC, bone marrow-derived MSC, bursa-derived MSC, or are tendon stem/progenitor cells.

5. The method of claim 1 , wherein the mesenchymal stem cells (MSC) are from the same species as the subject.

6. The method of claim 1 , wherein the mesenchymal stem cells (MSC) are from the same subject that is being treated.

7. The method of claim 1 , wherein the damaged tendon is damaged as a result of a tendinopathy.

8. The method of claim 1 , wherein the damaged tendon is damaged as a result of physical injury to the tendon.

9. The method of claim 1 , wherein the damaged tendon is a ruptured tendon.

10. The method of claim 1 , wherein the amount of microvesicles is administered locally into the tendon.

11. The method of claim 1 , wherein the amount of microvesicles is administered by injection.

12. The method of claim 1 , wherein the amount of microvesicles has been cryopreserved prior to administration.

13. The method of claim 1 , wherein the amount of microvesicles has been cryopreserved below 50° C.

14. A method of enhancing tenogenesis in a damaged tendon in a mammalian subject comprising administering to the subject an amount of microvesicles derived from mammalian mesenchymal stem cells effective to enhance tenogenesis, wherein the mesenchymal stem cells have been cultured on a silk scaffold prior to the microvesicles being derived from the mesenchymal stem cells.

15. The method of claim 14 , wherein the mesenchymal stem cells at P1 to P3 have been cultured on the silk scaffold.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2023
From: SUN, HUI B.
To: NEW YORK R&D CENTER FOR TRANSLATIONAL MEDICINE AND THERAPEUTICS, INC.
Reel/Frame 065573/0908 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2023
From: ALBERT EINSTEIN COLLEGE OF MEDICINE
To: SUN, HUI B.
Reel/Frame 065158/0948 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2023
From: SUN, HUI B.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 064904/0258 →
Continuity (2)
Provisional Application 62378392 · Aug 23, 2016
Related Publication 20210322482A1 · Oct 21, 2021